直肠癌MR分期:2012与2016年欧洲胃肠道和腹部放射学会(ESGAR)指南的比较
本研究纳入56例直肠癌患者,其中25例直接手术、31例术前行新辅助放化疗,所有患者均行3 T MRI进行局部分期。两位分别有20年和4年经验的放射科医生依据2012与2016 ESGAR指南评估T/N分期、MRF状态和EMVI。结果显示,对专家读者,两版指南在上述参数上无显著差异;对4年经验读者,N分期评估的组间一致度为「中等」,T再分期评估的组间一致度为「尚可」,采用2016 ESGAR指南可改善T再分期评估,尤其对非专家读者。
要点
- 2016 ESGAR指南可改善直肠癌MRI T再分期评估,尤其对非专家读者。
- 两版指南在专家读者的T/N分期、MRF状态和EMVI评估上无显著差异。
- 2016指南未改善淋巴结分期与再分期的诊断性能。
核心结论
- MRI是直肠癌分期/再分期的可靠方法,2016 ESGAR指南改善了T再分期评估(尤其对非专家读者),但未改善淋巴结分期与再分期的诊断性能。
研究设计与样本
- 比较性研究,纳入56例直肠癌患者,其中25/56例行直接手术,31例行新辅助放化疗后手术;所有患者行3 T MRI进行局部分期,由两位分别有20年和4年经验的放射科医生在互盲条件下依据2012和2016 ESGAR指南评估T和N分期、MRF状态和EMVI,并与病理结果对照。
诊断标准与关键数值
- 依据2012和2016 ESGAR指南分别评估T分期、N分期、T再分期、N再分期、MRF状态和EMVI。
- 对4年经验读者,2012与2016指南在N分期评估的一致度为「中等」,在T再分期评估的一致度为「尚可」。
临床应用与阅片要点
- 采用2016 ESGAR指南可能改善T再分期评估,尤其对非专家读者。
- 2016 ESGAR指南未改善淋巴结分期与再分期的诊断性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the adherence of the interpretation and reporting staging system, respectively proposed in the 2012 and 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guidelines for Magnetic Resonance Imaging (MRI) staging of rectal cancer, focusing on the improvement offered by the criteria introduced by 2016 ESGAR guidelines.
METHOD: Fifty-six patients affected by rectal cancer were included; 25/56 patients underwent upfront surgery; 31 underwent to neo-adjuvant chemo-radiotherapy before surgery. All patients underwent 3 T MRI examination for local staging. All MR exams were evaluated by two radiologists with 20- and 4-years' experience, who were blinded to each other; the T and N stages, the Mesorectal Fascia (MRF) status and the Extramural Vascular Invasion (EMVI) were assessed according to both 2012 and 2016 ESGAR guidelines. The correlation between radiological and pathological findings, as well as the MRI staging were evaluated.
RESULTS: As to the expert reviewer, no significant differences were found by comparing the MR T and N stages, T and N restaging, MRF status and EMVI according to 2012 and 2016 ESGAR guidelines. As to the 4-years' experience radiologist the MR staging agreement between 2012 and 2016 guidelines was "moderate" in N-stage evaluation and "fair" in T-restaging evaluation. No significant discrepancies were found for other parameters.
CONCLUSIONS: MRI is a reliable method in rectal cancer staging/restaging. The assessment of T-restaging is improved by adopting the 2016 ESGAR guidelines, especially for non-expert readers; this result could be justified by the introduction of diffusion-weighted imaging. On the contrary, the newest guidelines do not improve the diagnostic performance in assessing nodal staging and restaging.
引用
- Boraschi P, Donati F, Cervelli R, et al. MR staging of rectal cancer: Comparison between the 2012 and 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guidelines. Eur J Radiol. 2024. PMID: 39471550. doi:10.1016/j.ejrad.2024.111804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。